BRIEF-Merck’S Investigational Zilovertamab Vedotin At 1.75 mg/kg Dose Plus Standard Of Care Showed Promising Antitumor Activity

Reuters
May 30
BRIEF-Merck’S Investigational Zilovertamab Vedotin At 1.75 mg/kg Dose Plus Standard Of Care Showed Promising Antitumor Activity

May 30 (Reuters) - Merck & Co Inc MRK.N:

  • MERCK’S INVESTIGATIONAL ZILOVERTAMAB VEDOTIN AT 1.75 MG/KG DOSE PLUS STANDARD OF CARE SHOWED PROMISING ANTITUMOR ACTIVITY, INCLUDING COMPLETE RESPONSE RATE, IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL IN PHASE 2 PORTION OF WAVELINE-003 TRIAL

  • MERCK & CO INC - ZILOVERTAMAB VEDOTIN ACHIEVES 56.3% ORR IN RELAPSED/REFRACTORY DLBCL

  • MERCK & CO INC - ZILOVERTAMAB VEDOTIN UNDER EVALUATION IN PHASE 3 AND PHASE 2 STUDIES

Source text: ID:nBw884qGba

Further company coverage: MRK.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10